BRIM Biotechnology announced that the Board of Directors approved a seasoned equity offering that will issue 20 to 22.5 million shares of new stocks priced at 60-80 New Taiwan Dollars (~USD 2-2.67 per share). A total of ~USD 40-60 million will be raised to accelerate the development of several assets within its pipeline including the current phase 3 trial of lead asset BRM421 for dry eye disease (DED) in the US and speed up the enrollment of the phase 2 trial of BRM424 for neurotrophic keratitis (NK).
Kala Pharmaceuticals, Inc. announced positive safety data from the first cohort of the CHASE (Corneal Healing After Secretome therapy) Phase 2b clinical trial evaluating KPI-012, a human mesenchymal stem cell secretome (MCS-S), for the treatment of persistent corneal epithelial defect (PCED). The first cohort enrolled two patients, treated with a high dose of KPI-012 (3 U/mL) four times per day (QID). Both patients successfully completed at least one week of dosing with no safety issues observed.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5557
Published Date: Jan 23, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing prevalence and incidences of neurotrophic keratitis and upsurge in demand for novel therapies and treatment are the major factors driving the market growth.
The market size of neurotrophic keratitis is anticipated to attain a CAGR of ~17.07% over the forecast period, i.e., 2024-2036.
The major players in the market are Oyster Point Pharma, Inc., Neuroptica, Inc., Recordati Rare Diseases, KALA BIO, ReGenTree, LLC, BRIM Biotechnology, Inc., Bausch + Lomb Incorporated, Oculis, HLB Therapeutics
The drugs segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.